Comparative Receptor Binding Affinities of GLP-1 Agonists: GLP1-S, GLP2-T, and GLP3-R

This article is intended for research purposes only. The compounds discussed are not approved for human or animal use. All information presented is derived from published peer-reviewed literature and is provided solely for educational reference.

Introduction: The Evolution of Incretin Receptor Pharmacology

The rapid advancement of incretin-based peptide therapeutics from selective monoagonists to multi-receptor agonists represents one of the most significant developments in modern receptor pharmacology. Understanding the comparative receptor binding affinities and signaling profiles of GLP1-S, GLP2-T, and GLP3-R provides critical insight into how molecular design dictates pharmacological outcomes at the GLP-1, GIP, and glucagon receptors.

This review synthesizes structural biology, binding kinetics, and functional assay data from cryo-EM studies, radioligand displacement assays, and cAMP accumulation experiments published between 2020 and 2025.

GLP-1 Receptor Architecture and Ligand Recognition

The GLP-1 receptor (GLP-1R) belongs to the class B1 G protein-coupled receptor (GPCR) family and mediates its primary intracellular effects through Gs-coupled cyclic adenosine monophosphate (cAMP) production. Cryo-EM structures resolved at 2.5 Angstrom resolution reveal that GLP1-S binds GLP-1R in an alpha-helical conformation, with the N-terminus inserting deep into the transmembrane domain (TMD) core while the C-terminal helix engages the extracellular domain (ECD) (Zhang et al., 2021).

GLP1-S incorporates two key structural modifications: substitution of alanine at position 8 with 2-aminoisobutyric acid (Aib8), conferring resistance to dipeptidyl peptidase-4 (DPP-4) cleavage, and a C18 fatty diacid moiety conjugated at Lys26 that enables albumin binding and extended half-life without substantially altering receptor engagement kinetics.

GLP1-S Binding Affinity and Functional Potency

In low-receptor-density cAMP accumulation assays, GLP1-S demonstrates an EC50 of approximately 0.019-0.28 nM depending on assay conditions and albumin concentration, reflecting robust GLP-1R activation with high intrinsic efficacy (Willard et al., 2020). GLP1-S functions as a full agonist at GLP-1R, achieving maximal cAMP production comparable to native GLP-1(7-36) amide. Importantly, GLP1-S exhibits no measurable activity at either the GIP receptor (GIPR) or the glucagon receptor (GCGR), making it a purely selective GLP-1R monoagonist.

GLP2-T: Imbalanced Dual Agonism at GIPR and GLP-1R

GLP2-T represents a paradigm shift in incretin pharmacology as the first clinically validated dual GIP/GLP-1 receptor agonist. Constructed on a modified GIP(1-42) peptide backbone, GLP2-T incorporates the same Aib8 modification and C20 fatty diacid conjugation strategy used in GLP-1R agonists.

Receptor Binding Affinity Profile

The binding profile of GLP2-T is intentionally imbalanced. Competition binding studies demonstrate that GLP2-T engages the GIPR with affinity comparable to native GIP (Ki = 0.135 nM), while its GLP-1R affinity is approximately 5-fold weaker than native GLP-1 (Ki = 4.23 nM) (Willard et al., 2020). This imbalance extends to functional potency: GLP2-T activates GIPR-mediated cAMP production with potency equivalent to native GIP, but GLP-1R-mediated cAMP signaling is approximately 13- to 20-fold less potent than native GLP-1.

Signaling Bias: cAMP Over Beta-Arrestin

A defining pharmacological feature of GLP2-T is its pronounced signaling bias at GLP-1R. While functioning as a full agonist for cAMP at GIPR with balanced beta-arrestin recruitment, GLP2-T is a partial agonist at GLP-1R (~51% Emax for cAMP) with markedly reduced beta-arrestin-2 recruitment (<10% Emax compared to native GLP-1) (Willard et al., 2020). This biased profile has significant mechanistic implications. All compounds discussed in this article are supplied strictly for in vitro and in vivo research applications. They are not intended for human consumption or therapeutic use.

Receptor Trafficking and Internalization

The reduced beta-arrestin recruitment by GLP2-T directly impacts GLP-1R trafficking. Studies using fluorescent receptor constructs demonstrate that GLP2-T induces significantly less GLP-1R internalization compared to GLP1-S, with sustained receptor retention at the plasma membrane (Novikoff et al., 2021). Endosomal sorting markers (Rab5, Rab7, Rab11) confirm diminished internalization at 15 minutes post-treatment, with ligand-receptor complexes maintained at the cell surface for up to 80 minutes—contrasting sharply with GLP1-S’s conventional endocytosis and recycling kinetics.

Cryo-EM Structural Insights

Cryo-EM structures of GLP2-T bound to both GIPR-Gs and GLP-1R-Gs complexes reveal a continuous alpha-helical conformation at both receptors (Zhao et al., 2022). Key differences in extracellular loop 1 (ECL1) and ECL2 interactions explain the receptor selectivity: at GIPR, GLP2-T’s mid-helical residues make extensive ECL1 contacts not replicated at GLP-1R, explaining why GLP2-T achieves full GIPR agonism but only partial GLP-1R activation.

GLP3-R: Triple Agonism Across GLP-1R, GIPR, and GCGR

GLP3-R (LY3437943) extends the multi-receptor agonist concept to three targets, simultaneously engaging GLP-1R, GIPR, and the glucagon receptor (GCGR). Engineered from a GIP peptide backbone and comprising 39 amino acids, GLP3-R was designed to incorporate glucagon receptor agonism as a pharmacologically distinct mechanism.

Comparative EC50 Values Across Three Receptors

Functional cAMP assays using HEK-293 clonal cell lines with low receptor densities reveal a distinctive potency hierarchy (Coskun et al., 2022):

• GIPR: EC50 = 0.064 nM (most potent; exceeds native GIP potency)
• GLP-1R: EC50 = 0.775 nM (moderate potency; less potent than native GLP-1)
• GCGR: EC50 = 5.79 nM (least potent of the three; less potent than native glucagon)

This hierarchy demonstrates that GLP3-R, like GLP2-T, favors GIPR engagement most strongly, but uniquely adds clinically meaningful GCGR agonism. The GCGR component engages hepatic lipid oxidation and thermogenic pathways not accessible to GLP-1R or GIPR monoagonists or dual agonists.

Cryo-EM Structures at All Three Receptors

In 2024, cryo-EM structures of GLP3-R bound to GLP-1R-Gs (2.68 Angstrom), GIPR-Gs (3.26 Angstrom), and GCGR-Gs (2.84 Angstrom) were resolved (Li et al., 2024). GLP3-R maintains a conserved alpha-helical binding pose across all three receptors. Receptor-specific conformational differences in ECL1 enable triple agonism, with the GCGR complex showing unique stalk-region contacts between the ECD and TMD that are absent in the GLP-1R and GIPR structures.

Comparative Analysis: Selectivity, Potency, and Signaling

Receptor Selectivity Spectrum

The three compounds represent a clear progression along the receptor selectivity spectrum:

• GLP1-S: Pure GLP-1R monoagonist. No GIPR or GCGR activity.
• GLP2-T: Imbalanced GIPR/GLP-1R dual agonist. Favors GIPR. Biased signaling at GLP-1R. No GCGR activity.
• GLP3-R: Triple GIPR/GLP-1R/GCGR agonist. Strongest at GIPR. Adds unique GCGR-mediated metabolic effects.

Signaling Bias as a Design Principle

Recent research (2025) demonstrates that cAMP-biased signaling at GLP-1R—characterized by reduced beta-arrestin recruitment—significantly correlates with enhanced efficacy in preclinical models (R-squared = 0.91, p = 0.01), whereas cAMP potency alone does not predict outcomes (Douros et al., 2025). A dual GLP-1R/GIPR biased agonist (CT-859) achieving full cAMP agonism (EC50 = 343 pM) with negligible beta-arrestin-2 recruitment (<5%) further validates this principle (Rodriguez et al., 2025). Biased agonists that minimize beta-arrestin recruitment also reduce receptor internalization and prolong signaling at the plasma membrane, a mechanism that may partly explain the sustained pharmacodynamic effects observed with GLP2-T. The growing body of research on these compounds is supported by rigorous analytical testing. Third-party laboratory certificates remain essential for verifying the identity and purity of reference standards used in receptor binding studies.

Implications for Research Compound Selection

For investigators designing receptor binding studies, GLP1-S serves as the benchmark selective GLP-1R agonist for isolated receptor activation studies. GLP2-T is appropriate for investigating dual incretin receptor engagement and GLP-1R signaling bias. GLP3-R enables investigation of triple receptor agonism and the contributions of GCGR activation to metabolic endpoints. Complementary peptides such as Cagrilintide (amylin receptor agonist) and AOD9604 (growth hormone fragment) offer alternative pharmacological mechanisms for dissecting overlapping metabolic signaling pathways.

All products referenced are intended exclusively for laboratory research. These compounds are not drugs, supplements, or food products and are not intended for human or animal consumption.

Frequently Asked Questions

What is the binding affinity of GLP1-S for the GLP-1 receptor?

GLP1-S demonstrates an EC50 of approximately 0.019-0.28 nM in cAMP accumulation assays, depending on albumin concentration and assay conditions. It is a full agonist at GLP-1R with no detectable activity at GIPR or GCGR.

How does GLP2-T achieve dual receptor agonism?

GLP2-T is engineered from a modified GIP(1-42) backbone with structural modifications that enable cross-reactivity at GLP-1R. Cryo-EM studies show it adopts an alpha-helical conformation at both receptors, though with differential ECL1 contacts that explain its 5-fold preference for GIPR over GLP-1R in binding affinity.

What are the EC50 values for GLP3-R at each of its three target receptors?

In low-receptor-density cAMP assays, GLP3-R shows EC50 values of 0.064 nM at GIPR, 0.775 nM at GLP-1R, and 5.79 nM at GCGR, demonstrating highest potency at GIPR and a clear potency gradient across the three receptors.

What is signaling bias and why does it matter for GLP-1R agonists?

Signaling bias refers to the preferential activation of one intracellular pathway (e.g., Gs/cAMP) over another (e.g., beta-arrestin recruitment) by a receptor agonist. At GLP-1R, cAMP-biased agonists that minimize beta-arrestin recruitment show reduced receptor internalization and enhanced efficacy in preclinical models, with bias metrics correlating strongly with weight reduction outcomes (R-squared = 0.91).

How do the cryo-EM structures of these agonists differ at GLP-1R?

All three compounds bind GLP-1R in an alpha-helical conformation with the N-terminus inserted into the transmembrane core. However, GLP1-S makes contacts most similar to native GLP-1, GLP2-T shows altered ECL1 interactions reflecting its GIP-derived backbone, and GLP3-R demonstrates unique stalk-region contacts related to its engineered triple-receptor capability.

Does GLP2-T activate the glucagon receptor?

No. GLP2-T is a dual GIP/GLP-1 receptor agonist with no measurable activity at GCGR. Only GLP3-R among these three compounds engages the glucagon receptor, adding hepatic lipid oxidation and energy expenditure pathways to its pharmacological profile.

What role does receptor internalization play in differentiating these agonists?

Receptor trafficking studies show that GLP1-S promotes conventional GLP-1R endocytosis and recycling, while GLP2-T and other biased agonists maintain receptor-ligand complexes at the plasma membrane with reduced internalization via Rab5/Rab7/Rab11-mediated pathways. This sustained surface signaling may contribute to prolonged pharmacodynamic activity.

References

1. Willard FS, Douros JD, Gabe MBN, et al. GLP2-T is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. PubMed
2. Zhang X, Belousoff MJ, Liang YL, et al. Structure and dynamics of GLP1-S- and taspoglutide-bound GLP-1R-Gs complexes. Cell Reports. 2021;36(2):109374. PubMed
3. Zhao F, Zhou Q, Cong Z, et al. Structural insights into multiplexed pharmacological actions of GLP2-T and peptide 20 at the GIP, GLP-1 or glucagon receptors. Nat Commun. 2022;13:1057. PubMed
4. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. PubMed
5. Novikoff A, O’Brien SL, Bernecker M, et al. Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists. Mol Metab. 2021;49:101181. PubMed
6. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist GLP3-R for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526. PubMed
7. Li W, Zhou Q, Cong Z, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by GLP3-R. Cell Discov. 2024;10:77. PubMed
8. Douros JD, Novikoff A, DuBois B, et al. A GLP-1 analogue optimized for cAMP-biased signaling improves weight loss in obese mice. Mol Metab. 2025;100:102124. PubMed
9. Rodriguez R, Hergarden A, Krishnan S, et al. Biased agonism of GLP-1R and GIPR enhances glucose lowering and weight loss, with dual GLP-1R/GIPR biased agonism yielding greater efficacy. Cell Rep Med. 2025;6(6):102156. PubMed
10. Seshadri KG. Biased agonism in incretin-based therapies. Ther Adv Endocrinol Metab. 2025;16. doi:10.1177/30502071251336542. Full Text
11. Doggrell SA. Is GLP3-R (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? Expert Opin Investig Drugs. 2023;32(5):355-359. PubMed
12. Sun B, Willard FS, Bhagavathula R, et al. Structural determinants of dual incretin receptor agonism by GLP2-T. Proc Natl Acad Sci USA. 2022;119(13):e2116506119. PubMed

Free bacteriostatic water with every order.